François-Clément Bidard: ASCO mBC Session Will Feature persevERA Primary Results

François-Clément Bidard, Head of Center for Clinical Investigation CIC-2501 at Inserm, shared a post on LinkedIn:

” ‘Getting it right early in ER + mBC!’
(title of the ASCO abstract discussion by Matthew Goetz)

ASCO oral mBC session will feature back to back persevERA primary results (1L all comers trial, already known to be negative) and new results from SERENA-6 (1L adaptive oncology trial).”